SECAUCUS, N.J. - Quest Diagnostics (NYSE:DGX), a $20.2 billion healthcare diagnostics leader currently trading near its 52-week high at $179.88, announced Thursday the launch of a new pharmacogenomic ...

Quest Diagnostics is launching a new pharmacogenomics program designed to decode patients’ DNA to predict how they will respond to certain therapies and doses. The company said its test will span ...

SECAUCUS, N.J., Sept. 2, 2025 /PRNewswire/ -- The percentage of employees in the general U.S. workforce testing positive for fentanyl in random drug tests far exceeded those in pre-employment testing, ...

The $689 Cancerguard test is designed for annual screenings for adults ages 50-84 with no known cancer diagnosis in the last ...

Data from New Jersey-based drug test provider Quest Diagnostics involved an analysis of over 8 million workplace drug tests carried out during the last year—meaning the results are statistically ...

Disney+ is facing a new round of cancelations, but why? Find out the reasons in addition to the steps to cancel a ...

The U.S. Food and Drug Administration will rescind a rule that tightened regulations for clinical laboratories and gave the ...

The VENTANA HER2 (4B5) test is now CE-IVDR approved to aid in the assessment of HER2-ultralow status to identify metastatic breast cancer patients who may be eligible for treatment with ENHERTU. The ...

ST. LOUIS--(BUSINESS WIRE)--Clinicians worried about early-onset Alzheimer’s disease in patients with cognitive concerns between the ages of 50 and 55 years can now prescribe the PrecivityAD2™ blood ...

The Texas House on Tuesday greenlit plans to scrap the STAAR test, clearing a path to replace the state exams with three smaller ones given throughout the year. The plan passed, 78-58, over opposition ...

COPENHAGEN, DENMARK and BOSTON, MA, USA, August 28 - BioPorto A/S (BioPorto or Company) (CPH:BIOPOR), today announced ProNephro AKI (NGAL), the Company’s test for acute kidney injury, is now ...